U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H17N3O7S2
Molecular Weight 427.4549
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFOXITIN

SMILES

CO[C@]1(C(=O)N2C(=C(COC(=N)O)CS[C@]12[H])C(=O)O)N=C(Cc3cccs3)O

InChI

InChIKey=WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1

HIDE SMILES / InChI

Molecular Formula C16H17N3O7S2
Molecular Weight 427.4549
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/cefoxitin.html

Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria. The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Escherichia coli growth
Target ID: Klebsiella pneumoniae growth
Target ID: P08506
Gene ID: 945455.0
Gene Symbol: dacC
Target Organism: Escherichia coli (strain K12)
Target ID: P0AEB2
Gene ID: 945222.0
Gene Symbol: dacA
Target Organism: Escherichia coli (strain K12)
Target ID: P0AFI5
Gene ID: 946662.0
Gene Symbol: pbpG
Target Organism: Escherichia coli (strain K12)
Target ID: P02919
Gene ID: 944843.0
Gene Symbol: mrcB
Target Organism: Escherichia coli (strain K12)
Target ID: P0A3M6
Gene ID: 933948.0
Gene Symbol: penA
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
8.0 nM [IC50]
Target ID: Q8DR59
Gene ID: 934791.0
Gene Symbol: pbpA
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
6.8 nM [IC50]
Target ID: 933569.0
Gene Symbol: pbp2a
2.4 nM [IC50]
Target ID: 934893.0
Gene Symbol: pbp1b
0.145 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

1.26826565E12
Curative
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

1.26826565E12
Curative
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

1.26826565E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
24 μg/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
33.5 μg × h/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.67 h
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
27%
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g single, intramuscular
Dose: 2 g
Route: intramuscular
Route: single
Dose: 2 g
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hoigne's syndrome...
AEs leading to
discontinuation/dose reduction:
Hoigne's syndrome (1 patient)
Sources:
12 g 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g, 1 times / day
Sources:
unhealthy, 22 years
n = 1
Health Status: unhealthy
Condition: bacterial endocarditis
Age Group: 22 years
Sex: M
Population Size: 1
Sources:
2 g 3 times / day multiple, intravenous
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 45 years
n = 1
Health Status: unhealthy
Age Group: 45 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hemolytic anemia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia (1 patient)
Sources:
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hemolytic anemia, Pancytopenia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia (1 patient)
Pancytopenia (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hoigne's syndrome 1 patient
Disc. AE
2 g single, intramuscular
Dose: 2 g
Route: intramuscular
Route: single
Dose: 2 g
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Hemolytic anemia 1 patient
Disc. AE
2 g 3 times / day multiple, intravenous
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 45 years
n = 1
Health Status: unhealthy
Age Group: 45 years
Sex: F
Population Size: 1
Sources:
Hemolytic anemia 1 patient
Disc. AE
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
Pancytopenia 1 patient
Disc. AE
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Occurrence and transferability of beta-lactam resistance in Enterobacteriaceae isolated in Children's University Hospital in Bratislava.
2001
[Occurrence of beta-lactamase type ESBL and IBL in Pseudomonas aeruginosa rods].
2001
Antibacterial susceptibility of intestinal lactobacilli of healthy children.
2001
Improved methods for detection of methicillin-resistant Staphylococcus aureus.
2001 Apr
Clinical features of patients with invasive Eikenella corrodens infections and microbiological characteristics of the causative isolates.
2001 Apr
[Staphylococcus aureus: new detection of intrinsic resistance using the diffusion method].
2001 Apr
Mechanism of reaction of acyl phosph(on)ates with the beta-lactamase of Enterobacter cloacae P99.
2001 Apr 17
Prevalence and analysis of risk factors for infections caused by resistant Escherichia coli strains in Anhui, China.
2001 Aug
Antimicrobial resistance of strains of the Bacteroides fragilis group isolated from the intestinal tract of children and adults in Brazil.
2001 Aug
Natural antibiotic susceptibility of strains of the Enterobacter cloacae complex.
2001 Dec
A novel metallo-beta-lactamase, Mbl1b, produced by the environmental bacterium Caulobacter crescentus.
2001 Dec 14
Nosocomial bloodstream infection in pediatric patients: Siriraj Hospital, Bangkok; 1996-1999.
2001 Feb
A randomised controlled trial of antibiotic prophylaxis in elective caesarean delivery.
2001 Feb
Anti-anaerobic activity of antibacterial agents.
2001 Feb
Possible asymptomatic carrier of salmonella typhimurium in the preputium: a case report.
2001 Jan-Mar
Detection of beta-lactamase-mediated resistance.
2001 Jul
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.
2001 Jul
Laparoscopic management of gallstone ileus.
2001 Jul-Sep
Antibacterial effect of antibiotic solution on cellular viability in canine veins.
2001 Jun
Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone.
2001 Jun
Interaction energies between beta-lactam antibiotics and E. coli penicillin-binding protein 5 by reversible thermal denaturation.
2001 Jun
Influence of in-vivo endotoxin liberation on anti-anaerobic antimicrobial efficacy.
2001 Oct
[A study on beta-lactamase activity of biofilm Escherichia coli].
2001 Sep
Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals.
2001 Sep-Oct
Detection and typing of extended-spectrum beta-lactamases in clinical isolates of the family Enterobacteriaceae in a medical center in Turkey.
2001 Summer
Influence of failure of primary wound healing on subsequent recurrence of pilonidal sinus. combined prospective study and randomised controlled trial.
2002
Probing substrate binding to metallo-beta-lactamase L1 from Stenotrophomonas maltophilia by using site-directed mutagenesis.
2002
A luminescent Escherichia coli biosensor for the high throughput detection of beta-lactams.
2002 Apr
Klebsiella pneumoniae: epidemiology and analysis of risk factors for infections caused by resistant strains.
2002 Aug
[Identification of plasmid-encoded cephalosporinase ACC-1 among various enterobacteria (Klebsiella pneumoniae, Proteus mirabilis, Salmonella) isolated from a Tunisian hospital (Sfax 997-2000)].
2002 Feb
Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests.
2002 Feb
Characterization of blaCMY-11, an AmpC-type plasmid-mediated beta-lactamase gene in a Korean clinical isolate of Escherichia coli.
2002 Feb
Crystal structures of the Bacillus licheniformis BS3 class A beta-lactamase and of the acyl-enzyme adduct formed with cefoxitin.
2002 Feb 12
[Multidrug resistance in Klebsiella pneumoniae: multicenter study].
2002 Jan
Natural antibiotic susceptibility and biochemical profiles of Yersinia enterocolitica-like strains: Y. bercovieri, Y. mollaretii, Y. aldovae and 'Y. ruckeri'.
2002 Jan
Primary liver abscess caused by one clone of Klebsiella pneumoniae with two colonial morphotypes and resistotypes.
2002 Jan
Comparison of several methods used for the determination of cephalosporins. Analysis of cephalexin in pharmaceutical samples.
2002 Jul 1
Nontuberculous mycobacterial pulmonary diseases in immunocompetent patients.
2002 Jul-Sep
Escherichia coli isolated from seafood: toxicity and plasmid profiles.
2002 Mar
The ACT-1 plasmid-encoded AmpC beta-lactamase is inducible: detection in a complex beta-lactamase background.
2002 Mar
Further modification of the Hodge test to screen AmpC beta-lactamase (CMY-1)-producing strains of Escherichia coli and Klebsiella pneumoniae.
2002 Nov
[Trends in antimicrobial utilization in a university hospital, 1990-1996].
2002 Oct
Klebsiella and enterobacter: antibiotic resistance and treatment implications.
2002 Sep
Automated ribotyping and pulsed-field gel electrophoresis for rapid identification of multidrug-resistant Salmonella serotype newport.
2003 Apr
Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea.
2003 Apr
Group 1 beta-lactamases of Aeromonas caviae and their resistance to beta-lactam antibiotics.
2003 Mar
Isolation of Escherichia coli O157:H7 from intact colon fecal samples of swine.
2003 Mar
Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period.
2003 Mar
Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates.
2003 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Adults The usual adult dosage range is 1 gram to 2 grams every six to eight hours.
Route of Administration: Intravenous
CEFOXITIN inhibited Mycobacterium fortuitum growth with MIC 32 ug/ml
Substance Class Chemical
Created
by admin
on Sat Jun 26 00:24:18 UTC 2021
Edited
by admin
on Sat Jun 26 00:24:18 UTC 2021
Record UNII
6OEV9DX57Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFOXITIN
INN   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
J01DC01
Code English
CEFOXITIN [WHO-DD]
Common Name English
(6R,7S)-3-(HYDROXYMETHYL)-7-METHOXY-8-OXO-7-(2-(2-THIENYL)ACETAMIDO)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID CARBAMATE (ESTER)
Systematic Name English
CEFOXITIN [USAN]
Common Name English
CEFOXITIN [VANDF]
Common Name English
CEFOXITIN [USP-RS]
Common Name English
CEFOXITIN [ORANGE BOOK]
Common Name English
CEFOXITIN [MI]
Common Name English
CEFOXITIN [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
LIVERTOX 167
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
WHO-VATC QJ01DC01
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000175488
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NCI_THESAURUS C357
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
WHO-ATC J01DC01
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL996
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
MERCK INDEX
M3208
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
550
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
ECHA (EC/EINECS)
252-641-2
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
CAS
35607-66-0
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
WIKIPEDIA
CEFOXITIN
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
LACTMED
Cefoxitin
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
USP_CATALOG
1098107
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY USP-RS
INN
3397
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
EVMPD
SUB07409MIG
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
MESH
D002440
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
RXCUI
2189
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY RxNorm
FDA UNII
6OEV9DX57Y
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
DRUG BANK
DB01331
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
NCI_THESAURUS
C61665
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
EPA CompTox
35607-66-0
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
PUBCHEM
441199
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC